Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

Conclusions
Repopulation kinetics of the evaluated peripheral lymphocyte subsets did not predict autoimmune AE occurrence or disease activity, including return of disease activity after 2 alemtuzumab courses. Further study is needed to investigate potential antigen-level markers of treatment response.

Source: Neurology Neuroimmunology and Neuroinflammation - October 28, 2019 Category: Neurology Authors: Wiendl, H., Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N., Chung, L., Jacobs, A. K., Hogan, R. J., Wychowski, L. V., Van Wijmeersch, B., On behalf of the CARE-MS I, CARE-MS II, and CAMMS03409 Investigators Tags: MRI, Autoimmune diseases, Clinical trials Randomized controlled (CONSORT agreement), Multiple sclerosis Article Source Type: research